NMRA Stock Forecast & Price Target

Neumora Therapeutics is viewed positively because its pipeline still offers multiple near- to medium-term catalysts even after navacaprant’s Phase 3 MDD failure, with focus shifting to NMRA-898, NMRA-511, and NMRA-215 across underserved neuropsychiatric and neurodegenerative indications. The company’s lead asset was previously expected to support US sales potential of $750 million in 2028 and $3 billion at peak, and the broader portfolio includes seven clinical and preclinical programs with first- or best-in-class potential. Financially, the 35% workforce reduction should save about $10 million annually, and current cash is expected to fund operations into 3Q27, supporting execution through key data readouts.

Neumora Therapeutics is facing a materially negative fundamental outlook because navacaprant failed to separate from placebo in KOASTAL-2 and KOASTAL-3 on both the primary MADRS endpoint and the key SHAPS endpoint, undermining the core KORA thesis. The reported results were essentially flat versus placebo, including -12.2 vs -12.0 in KOASTAL-2 and -12.1 vs -12.1 after study optimizations, suggesting the mechanism may not be central to treating anhedonia. In response, the company is discontinuing navacaprant development and cutting 35% of the workforce, which should drive $10M in annualized savings and reflects a necessary but painful reset to a mid-stage biotech profile.